FeLV-A and FeLV-B in cats at a veterinary hospital in Northern Italy

Veterinary research communications · 2024

In plain language

This study examined 26 cats with a positive FeLV antigen test at a veterinary hospital in Northern Italy. Sequence analysis identified FeLV-A in 15 cats and also FeLV-B in five of them. One cat with both subtypes was recorded as having leucemic lymphoma, but this does not show that FeLV-B caused that cancer. The selection of cats and the limitations of the tests prevent conclusions about how common these subtypes are in the population or how they relate to cancer risk.

Scientific detail

The clinical study published in Veterinary Research Communications in 2024 (doi: 10.1007/s11259-024-10380-6) provides direct molecular evidence from cats referred to a veterinary teaching hospital in Northern Italy. Results reports 26 FeLV antigen-positive cats; Methods specifies antigen positivity as an inclusion criterion but does not state the sample size. qPCR detected FeLV proviral DNA in 22 of the 26 cats. This proportion describes detection in a selected clinical sample, not a validated estimate of diagnostic sensitivity or population prevalence. Technical assay controls do not replace a clinical comparison group. The four antigen-positive, qPCR-negative results remained unresolved.

Sequencing identified FeLV-A in 15 cats, with FeLV-B also detected in five of these cats. env sequences could not be obtained from some qPCR-detected viruses, limiting subtype ascertainment. Most sequenced amplicons from PCRs 5 and 6, which were intended to amplify only FeLV-B, clustered with endogenous FeLV. A positive amplification result from these assays alone therefore does not establish FeLV-B identity in this study. The proposed explanation for the low specificity remains tentative.

Table 2 records cat 324 as having leucemic lymphoma and env sequences assigned to both FeLV-A and FeLV-B. This is a single recorded clinical co-occurrence. The supplied text does not describe confirmation of the lymphoma diagnosis, viral analysis of tumor tissue, or integration-site evidence. This observation does not establish that FeLV-B caused the lymphoma, increases neoplasia risk, or has a specific oncogenic mechanism in these cats.

The authors state that the sample size and inclusion criteria prevent epidemiological conclusions. Sick cats were overrepresented in the hospital population. The supplied text also contains inconsistent counts of symptomatic and asymptomatic cats and conflicting statements about signalment associations. Validation of the assays in antigen-negative cats was proposed, but results of that validation were not reported. The empirical claims in the knowledge object are classified as level C evidence. Whether FeLV-B is associated with feline neoplasms remains an open question: the authors propose improved subtype identification and further research into correlations with neoplasms.

What we know

In this selected cohort, qPCR detected FeLV proviral DNA in 22 of 26 antigen-positive cats. Sequencing identified FeLV-A in 15 cats and also FeLV-B in five of them, including one cat recorded as having leucemic lymphoma. Most sequenced amplicons from two assays intended to target FeLV-B clustered with endogenous FeLV. These findings, classified as level C evidence, document detections and a clinical co-occurrence, with incomplete subtype ascertainment; they do not establish causation or subtype-specific cancer risk.

What we don't know

This study does not resolve whether FeLV-B is associated with feline neoplasms or establish a specific oncogenic mechanism in these cats. It also cannot provide estimates of population subtype prevalence or validated diagnostic sensitivity. The four antigen-positive, qPCR-negative results, subtype identification for viruses without env sequences, and the explanation for the low specificity of the assays intended to target FeLV-B remain unresolved. The proposed validation in antigen-negative cats was not reported.